Date: November 19, 2021

Administrative Circular: 2021:46

ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization,
Part 4 – Biological Products

Part 4 – Biological Products

COVID-19 Vaccines

COVID-19 Vaccine Eligibility

- ‘Pediatric populations – 5 to 11 years of age (inclusive)’ has been added.

Please remove page numbers: 1-2 dated November 15, 2021
Please add new page numbers: 1-2 dated November 19, 2021

COVID-19 mRNA Vaccine COMIRNATY™ (Pfizer-BioNTech) (Adult/Adolescent)

- The product name has been updated to differentiate from the pediatric formulation.
- Doses and Schedules: Footnote A has been revised to indicate that the minimum age for vaccine receipt is based on age at presentation (i.e., the Pfizer COVID-19 vaccine adult/adolescent formulation may be offered to individuals on or after their 12th birthday).

Please remove page numbers: 1-6 dated November 12, 2021
Please add new page numbers: 1-6 dated November 19, 2021

COVID-19 mRNA Vaccine COMIRNATY™ (Pfizer-BioNTech) (Pediatric)

- This new product page has been added.

Please add new page numbers: 1-5 dated November 19, 2021

COVID-19 Vaccine VAXZEVRIA™/COVISHIELD (AstraZeneca/Verity Pharmaceuticals)

- Adverse Events has been updated to include rare cases of Guillain-Barré Syndrome.

Please remove page numbers: 1-4 dated November 12, 2021
Please add new page numbers: 1-4 dated November 19, 2021
COVID-19 Vaccine (Ad26.COV2.S [recombinant]) (Janssen Inc.)

- Adverse Events has been updated to include rare cases of Guillain-Barré Syndrome.

Please remove page numbers: 1-4 dated November 12, 2021
Please add new page numbers: 1-4 dated November 19, 2021

Please also remove the Title Page and Table of Contents for Part 4 – Biological Products dated November 2021 and replace with the enclosed updated Title Page and Table of Contents dated November 19, 2021.

Supporting resources:

Guidance Document on the Management of Inadvertent Vaccine Errors

Content has been added to address the management of potential inadvertent vaccine errors related to booster doses, as well as the Pfizer-BioNTech COVID-19 Vaccine Pediatric formulation (10 mcg).
If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,

Monika Naus MD MHSc FRCPC FACPM
Medical Director
Communicable Diseases & Immunization Service
BC Centre for Disease Control

pc:
- Provincial Health Officer
  - Dr. Bonnie Henry
- Dr. Reka Gustafson
  - Vice President, Public Health & Wellness, PHSA & Deputy Provincial Health Officer
- Deputy Provincial Health Officer
  - Dr. Martin Lavoie

BC Ministry of Health, Population & Public Health Division:
- Brian Sagar
  - Senior Director Communicable Disease, Population and Public Health Division
- Bernard Achampong
  - Executive Director, Public Health, Planning and Prevention, Population and Public Health Division